Treatment with anti-JAM-C antibody resulted in a nonsignificant decrease of mean blood glucose levels in RIP-LCMV-NP mice (Number 3B, right panel)
Treatment with anti-JAM-C antibody resulted in a nonsignificant decrease of mean blood glucose levels in RIP-LCMV-NP mice (Number 3B, right panel). not accelerate diabetes in the RIP-LCMV model. In summary, our data suggest that JAM-C might be involved in the final methods of trafficking and transmigration of antigen-specific autoaggressive T-cells to the islets of Langerhans.…